| ■ 영문 제목 : Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027
|
 | ■ 상품코드 : IRTNTR72723-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 2월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,600,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사의 본 연구 보고서에 따르면 세계의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모가 2022년에서 2027년 사이에 1,657.08백만 달러에 이르며, 예측 기간 동안 연평균 12.92% 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 BCL-2 (B 세포 림프종 2) 억제제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 제품별 (병용 요법, 단독 요법) 분석, 종류별 (미만성 대세포형 B세포림프종 (DLBCL), 여포성 림프종, 만성 림프성 백혈병, 맨틀 세포 림프종 (MCL)) 분석, 고객 현황, 지역별 현황 (북미, 아시아 태평양, 유럽, 중동 및 아프리카, 남미, 미국, 중국, 독일, 영국, 일본) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma 등의 기업 정보가 포함되어 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 BCL-2 (B세포 림프종 2) 억제제 시장 규모 : 제품별
- 병용 요법에 사용되는 BCL-2 (B세포 림프종 2) 억제제의 시장 규모
- 단독 요법에 사용되는 BCL-2 (B세포 림프종 2) 억제제의 시장 규모
・세계의 BCL-2 (B세포 림프종 2) 억제제 시장 규모 : 종류별
- 미만성 대세포형 B세포림프종 (DLBCL)에 사용되는 억제제의 시장 규모
- 여포성 림프종에 사용되는 억제제의 시장 규모
- 만성 림프성 백혈병에 사용되는 억제제의 시장 규모
- 맨틀 세포 림프종 (MCL)에 사용되는 억제제의 시장 규모
・고객 현황
・지역별 현황
- 북미의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 유럽의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 아시아 태평양의 BCL-2 (B세포 림프종 2) 억제제 시장 규모
- 기타 지역의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 미국의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 캐나다의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 독일의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 영국의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
- 일본의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 BCL-2 (B 세포 림프종 2) 억제제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 BCL-2 (B 세포 림프종 2) 억제제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global BCL-2 (B-cell Lymphoma 2) Inhibitors Market 2023-2027Technavio has been monitoring the BCL-2 (B-cell Lymphoma 2) inhibitors market and is forecast to grow by $1,657.08 mn during 2022-2027, accelerating at a CAGR of 12.92% during the forecast period. Our report on the BCL-2 (B-cell Lymphoma 2)inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.
Technavio’s BCL-2 (B-cell Lymphoma 2) inhibitors market is segmented as below:
By Product
• Combination therapy
• Monotherapy
By Type
• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma
• Chronic lymphocytic leukemia
• Mantle cell lymphoma (MCL)
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the increase of patient assistance programs as one of the prime reasons driving the BCL-2 (B-cell Lymphoma 2) inhibitors market growth during the next few years. Also, growing approval of combination therapy and development of novel formulations will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the BCL-2 (B-cell Lymphoma 2) inhibitors market covers the following areas:
• BCL-2 (B-cell Lymphoma 2) inhibitors market sizing
• BCL-2 (B-cell Lymphoma 2) inhibitors market forecast
• BCL-2 (B-cell Lymphoma 2) inhibitors market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BCL-2 (B-cell Lymphoma 2) inhibitors market vendors that include Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc. Also, the BCL-2 (B-cell Lymphoma 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 – 2021 ($ million)
o 4.2 Product Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.3 Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Combination therapy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
o 6.4 Monotherapy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Product
o Exhibit 42: Market opportunity by Product ($ million)
o Exhibit 43: Data Table on Market opportunity by Product ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 44: Chart on Type – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 46: Chart on Comparison by Type
o Exhibit 47: Data Table on Comparison by Type
o 7.3 Diffuse large B-cell lymphoma (DLBCL) – Market size and forecast 2022-2027
o Exhibit 48: Chart on Diffuse large B-cell lymphoma (DLBCL) – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Diffuse large B-cell lymphoma (DLBCL) – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) – Year-over-year growth 2022-2027 (%)
o 7.4 Follicular lymphoma – Market size and forecast 2022-2027
o Exhibit 52: Chart on Follicular lymphoma – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Follicular lymphoma – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Follicular lymphoma – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Follicular lymphoma – Year-over-year growth 2022-2027 (%)
o 7.5 Chronic lymphocytic leukemia – Market size and forecast 2022-2027
o Exhibit 56: Chart on Chronic lymphocytic leukemia – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Chronic lymphocytic leukemia – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Chronic lymphocytic leukemia – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Chronic lymphocytic leukemia – Year-over-year growth 2022-2027 (%)
o 7.6 Mantle cell lymphoma (MCL) – Market size and forecast 2022-2027
o Exhibit 60: Chart on Mantle cell lymphoma (MCL) – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Mantle cell lymphoma (MCL) – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Mantle cell lymphoma (MCL) – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Mantle cell lymphoma (MCL) – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Type
o Exhibit 64: Market opportunity by Type ($ million)
o Exhibit 65: Data Table on Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2022-2027 (%)
o Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 95: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 99: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 France – Market size and forecast 2022-2027
o Exhibit 103: Chart on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on France – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on France – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 115: AbbVie Inc. – Overview
o Exhibit 116: AbbVie Inc. – Product / Service
o Exhibit 117: AbbVie Inc. – Key news
o Exhibit 118: AbbVie Inc. – Key offerings
o 12.4 Abcam plc
o Exhibit 119: Abcam plc – Overview
o Exhibit 120: Abcam plc – Product / Service
o Exhibit 121: Abcam plc – Key news
o Exhibit 122: Abcam plc – Key offerings
o 12.5 Amgen Inc.
o Exhibit 123: Amgen Inc. – Overview
o Exhibit 124: Amgen Inc. – Product / Service
o Exhibit 125: Amgen Inc. – Key offerings
o 12.6 Ascentage Pharma Group International
o Exhibit 126: Ascentage Pharma Group International – Overview
o Exhibit 127: Ascentage Pharma Group International – Product / Service
o Exhibit 128: Ascentage Pharma Group International – Key offerings
o 12.7 AstraZeneca Plc
o Exhibit 129: AstraZeneca Plc – Overview
o Exhibit 130: AstraZeneca Plc – Product / Service
o Exhibit 131: AstraZeneca Plc – Key news
o Exhibit 132: AstraZeneca Plc – Key offerings
o 12.8 BeiGene Ltd.
o Exhibit 133: BeiGene Ltd. – Overview
o Exhibit 134: BeiGene Ltd. – Business segments
o Exhibit 135: BeiGene Ltd. – Key offerings
o Exhibit 136: BeiGene Ltd. – Segment focus
o 12.9 Bio Techne Corp.
o Exhibit 137: Bio Techne Corp. – Overview
o Exhibit 138: Bio Techne Corp. – Business segments
o Exhibit 139: Bio Techne Corp. – Key news
o Exhibit 140: Bio Techne Corp. – Key offerings
o Exhibit 141: Bio Techne Corp. – Segment focus
o 12.10 Biorbyt Ltd.
o Exhibit 142: Biorbyt Ltd. – Overview
o Exhibit 143: Biorbyt Ltd. – Product / Service
o Exhibit 144: Biorbyt Ltd. – Key offerings
o 12.11 Bristol Myers Squibb Co.
o Exhibit 145: Bristol Myers Squibb Co. – Overview
o Exhibit 146: Bristol Myers Squibb Co. – Product / Service
o Exhibit 147: Bristol Myers Squibb Co. – Key news
o Exhibit 148: Bristol Myers Squibb Co. – Key offerings
o 12.12 F. Hoffmann La Roche Ltd.
o Exhibit 149: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 150: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 151: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 152: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 153: F. Hoffmann La Roche Ltd. – Segment focus
o 12.13 Merck and Co. Inc.
o Exhibit 154: Merck and Co. Inc. – Overview
o Exhibit 155: Merck and Co. Inc. – Business segments
o Exhibit 156: Merck and Co. Inc. – Key news
o Exhibit 157: Merck and Co. Inc. – Key offerings
o Exhibit 158: Merck and Co. Inc. – Segment focus
o 12.14 Novartis AG
o Exhibit 159: Novartis AG – Overview
o Exhibit 160: Novartis AG – Business segments
o Exhibit 161: Novartis AG – Key offerings
o Exhibit 162: Novartis AG – Segment focus
o 12.15 Santa Cruz Biotechnology Inc.
o Exhibit 163: Santa Cruz Biotechnology Inc. – Overview
o Exhibit 164: Santa Cruz Biotechnology Inc. – Product / Service
o Exhibit 165: Santa Cruz Biotechnology Inc. – Key offerings
o 12.16 Seagen Inc.
o Exhibit 166: Seagen Inc. – Overview
o Exhibit 167: Seagen Inc. – Product / Service
o Exhibit 168: Seagen Inc. – Key offerings
o 12.17 Servier
o Exhibit 169: Servier – Overview
o Exhibit 170: Servier – Business segments
o Exhibit 171: Servier – Key offerings
o Exhibit 172: Servier – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 173: Inclusions checklist
o Exhibit 174: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 175: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 176: Research methodology
o Exhibit 177: Validation techniques employed for market sizing
o Exhibit 178: Information sources
o 13.5 List of abbreviations
o Exhibit 179: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Product – Market share 2022-2027 (%)
Exhibits31: Data Table on Product – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Product ($ million)
Exhibits43: Data Table on Market opportunity by Product ($ million)
Exhibits44: Chart on Type – Market share 2022-2027 (%)
Exhibits45: Data Table on Type – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Type
Exhibits47: Data Table on Comparison by Type
Exhibits48: Chart on Diffuse large B-cell lymphoma (DLBCL) – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Diffuse large B-cell lymphoma (DLBCL) – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Diffuse large B-cell lymphoma (DLBCL) – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Diffuse large B-cell lymphoma (DLBCL) – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Follicular lymphoma – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Follicular lymphoma – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Follicular lymphoma – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Follicular lymphoma – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Chronic lymphocytic leukemia – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Chronic lymphocytic leukemia – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Chronic lymphocytic leukemia – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Chronic lymphocytic leukemia – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Mantle cell lymphoma (MCL) – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Mantle cell lymphoma (MCL) – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Mantle cell lymphoma (MCL) – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Mantle cell lymphoma (MCL) – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Type ($ million)
Exhibits65: Data Table on Market opportunity by Type ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2022-2027 (%)
Exhibits68: Data Table on Market share by geography 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on France – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on France – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on France – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on France – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AbbVie Inc. – Overview
Exhibits116: AbbVie Inc. – Product / Service
Exhibits117: AbbVie Inc. – Key news
Exhibits118: AbbVie Inc. – Key offerings
Exhibits119: Abcam plc – Overview
Exhibits120: Abcam plc – Product / Service
Exhibits121: Abcam plc – Key news
Exhibits122: Abcam plc – Key offerings
Exhibits123: Amgen Inc. – Overview
Exhibits124: Amgen Inc. – Product / Service
Exhibits125: Amgen Inc. – Key offerings
Exhibits126: Ascentage Pharma Group International – Overview
Exhibits127: Ascentage Pharma Group International – Product / Service
Exhibits128: Ascentage Pharma Group International – Key offerings
Exhibits129: AstraZeneca Plc – Overview
Exhibits130: AstraZeneca Plc – Product / Service
Exhibits131: AstraZeneca Plc – Key news
Exhibits132: AstraZeneca Plc – Key offerings
Exhibits133: BeiGene Ltd. – Overview
Exhibits134: BeiGene Ltd. – Business segments
Exhibits135: BeiGene Ltd. – Key offerings
Exhibits136: BeiGene Ltd. – Segment focus
Exhibits137: Bio Techne Corp. – Overview
Exhibits138: Bio Techne Corp. – Business segments
Exhibits139: Bio Techne Corp. – Key news
Exhibits140: Bio Techne Corp. – Key offerings
Exhibits141: Bio Techne Corp. – Segment focus
Exhibits142: Biorbyt Ltd. – Overview
Exhibits143: Biorbyt Ltd. – Product / Service
Exhibits144: Biorbyt Ltd. – Key offerings
Exhibits145: Bristol Myers Squibb Co. – Overview
Exhibits146: Bristol Myers Squibb Co. – Product / Service
Exhibits147: Bristol Myers Squibb Co. – Key news
Exhibits148: Bristol Myers Squibb Co. – Key offerings
Exhibits149: F. Hoffmann La Roche Ltd. – Overview
Exhibits150: F. Hoffmann La Roche Ltd. – Business segments
Exhibits151: F. Hoffmann La Roche Ltd. – Key news
Exhibits152: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits153: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits154: Merck and Co. Inc. – Overview
Exhibits155: Merck and Co. Inc. – Business segments
Exhibits156: Merck and Co. Inc. – Key news
Exhibits157: Merck and Co. Inc. – Key offerings
Exhibits158: Merck and Co. Inc. – Segment focus
Exhibits159: Novartis AG – Overview
Exhibits160: Novartis AG – Business segments
Exhibits161: Novartis AG – Key offerings
Exhibits162: Novartis AG – Segment focus
Exhibits163: Santa Cruz Biotechnology Inc. – Overview
Exhibits164: Santa Cruz Biotechnology Inc. – Product / Service
Exhibits165: Santa Cruz Biotechnology Inc. – Key offerings
Exhibits166: Seagen Inc. – Overview
Exhibits167: Seagen Inc. – Product / Service
Exhibits168: Seagen Inc. – Key offerings
Exhibits169: Servier – Overview
Exhibits170: Servier – Business segments
Exhibits171: Servier – Key offerings
Exhibits172: Servier – Segment focus
Exhibits173: Inclusions checklist
Exhibits174: Exclusions checklist
Exhibits175: Currency conversion rates for US$
Exhibits176: Research methodology
Exhibits177: Validation techniques employed for market sizing
Exhibits178: Information sources
Exhibits179: List of abbreviations
|
| ※본 조사보고서 [세계의 BCL-2 (B세포 림프종 2) 억제제 시장 (2023년~2027년)] (코드 : IRTNTR72723-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 BCL-2 (B세포 림프종 2) 억제제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요! 세계의 BCL-2 (B세포 림프종 2) 억제제 시장 (2023년~2027년)
